Daniel Lenihan, MD
St. Louis, MO, USA
Daniel Lenihan is a professor and the director of the Cardio-Oncology Center of Excellence at Washington University, St Louis, USA.
Dr Lenihan has been active in cardio-oncology and heart failure for over 20 years. The main focus of his efforts have included haemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers and optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer.
His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. Dr Lenihan is the principal investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma, and the recently completed PREDICT study, a large multicentre prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis.
Dr Lenihan recently moved to Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable cardio-oncology fellowship training programme, and he continues to foster collaboration among a host of colleagues both regionally, nationally and throughout the world. Dr Lenihan is the current president of the International Cardio-Oncology Society (ICOS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy. He is also a deputy editor for the new JACC: CardioOncology journal, from the Journal of the American College of Cardiology (JACC) family of journals.